Development of and Feasibility Testing of Decision Support for Patients Who Are Candidates for an Implantable Defibrillator
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Cardiovascular Disease
- Sponsor
- McMaster University
- Enrollment
- 82
- Locations
- 1
- Primary Endpoint
- Primary Outcomes(composite): i) decision aid development, and ii) decision aid evaluation.
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
Sudden cardiac death (SCD) due to a ventricular arrhythmia is a serious cause of cardiovascular death in Canada. The implantable cardioverter defibrillator (ICD) offers high-risk patients a treatment option to reduce the incidence of SCD by delivering an internal shock to restore a normal rhythm, if needed. Definitive evidence has established the effectiveness of the ICD for reducing mortality when used as prophylaxis for SCD (a primary prevention indication). Approximately 3,700 new candidates accrue annually. Practice guidelines define the criteria to determine patient ICD candidacy for primary prevention. However, in addition to SCD risk, ICD candidates may have chronic diseases such as diabetes, renal insufficiency, hypertension, and atrial fibrillation. Thus, balancing the benefits and risks of an ICD can become complex, particularly when competing mortality risks are present. Research has recognized human costs associated with device complications and shocks affecting psychological, health related quality of life (HRQL), and morbidity outcomes. The complexities surrounding the long-term benefits/risks, complications, replacements, and shocks, warrant decision support to prepare patients to make decisions. In Canada, there is no clear framework to support patients' decision-making in the context of ICD treatment options. Decision support, using a decision aid, could moderate treatment related uncertainty and prepare patients to make active, informed, quality decisions.
Objectives: 1) develop a decision aid for ICD candidates to support quality decision-making (informed, deliberate, values-based choices), 2) to evaluate the decision aid, and 3) to determine the feasibility of conducting a trial.
Investigators
Sandra Carroll
Assistant Professor
McMaster University
Eligibility Criteria
Inclusion Criteria
- •Referred for consideration of an ICD(non-CRT)for a primary prevention indication
- •English speaking
- •able to provide informed consent
Exclusion Criteria
- •unable to understand the decision aid due to a language barrier or visual impairment
- •referred for secondary prevention indication
Outcomes
Primary Outcomes
Primary Outcomes(composite): i) decision aid development, and ii) decision aid evaluation.
Time Frame: Phase 1-2 (1- year)
Development of the decision aid will be guided by the Ottawa Decision Support Framework (ODSF). Evaluation will include the Decision Aid Acceptability questionnaire comprised of 10 items including comprehensibility, balance of presentation of information, and overall suitability.
Secondary Outcomes
- Sure Test(Pre-consultation - baseline visit)
- Pilot RCT (feasibility)(Pre-Post consultation - participants will be followed until consultation is completed and at 3 months post consultation (average of 16 weeks))
- Decision quality measures(Pre consultation (baseline visit))
- Decisional Conflict Scale (DCS)(Pre and post consultation- (intervention and usual care group, baseline visit + 1 week post consult))
- The Center for Epidemiologic Studies Depression Scale (CES-D)(Pre consultation - baseline visit (intervention and usual care))
- Preparation for Decision Making scale(Post consultation - up to two weeks post baseline visit (intervention group))
- The Medical Outcomes Trust Short Form (SF-36v2)(Pre consultation - baseline visit (intervention and usual care))